-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7

Benzinga·10/06/2026 12:02:33
Guggenheim analyst Delma Caiati initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announces Price Target of $7.